Insulet (PODD) vs Solventum (SOLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Solventum (SOLV) has outperformed Insulet (PODD) over the past year, gaining 19.0% versus a loss of 57.1%. Solventum is the larger company by market cap ($14.62 billion vs $9.32 billion), about 1.6 times the size, while Insulet is growing revenue faster (+30.7% vs +0.9%). On valuation, Solventum trades at a lower forward P/E (11.9x vs 17.4x for Insulet).
Solventum converts more of its revenue into profit, with a net margin of 18.7% versus 9.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PODD | SOLV |
|---|---|---|
| Share price | $134.36 | $85.88 |
| Market cap | $9.32B | $14.62B |
| 1-day change | -0.27% | -1.33% |
| YTD return | -52.73% | +8.38% |
| 1-year return | -57.14% | +19.01% |
| 5-year return | -55.29% | — |
| P/E ratio (TTM) | 25.16 | 10.51 |
| Forward P/E | 17.38 | 11.88 |
| EPS (TTM) | $5.34 | $8.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.71B | $8.32B |
| Revenue growth (YoY) | +30.73% | +0.86% |
| Net income (latest FY) | $247.10M | $1.56B |
| Gross margin | 71.63% | 53.47% |
| Operating margin | 17.50% | 26.20% |
| Net margin | 9.12% | 18.69% |
| 52-week high | $354.88 | $94.16 |
| 52-week low | $126.40 | $62.38 |
| Distance from 52-week high | -62.14% | -8.79% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +27.24% | +9.82% |
| Average volume | 1.69M | 1.02M |
| Shares outstanding | 69.35M | 170.22M |
| Employees | 5,400 | 20,584 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SOLV has outperformed PODD by 76.1 percentage points over the past year.
- Insulet trades at a higher earnings multiple (25.2x vs 10.5x trailing P/E).
- Solventum is more profitable, keeping 18.7 cents of every revenue dollar as net income versus 9.1 cents for Insulet.
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs +0.86%).
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
About Solventum
SOLV stock →Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Health Care · Medical/Dental Instruments · 20,584 employees
PODD vs SOLV FAQ
Which is bigger, Insulet or Solventum?
Solventum (SOLV) is larger, with a market capitalization of $14.62B compared with $9.32B for Insulet (PODD).
Which stock has performed better over the past year, PODD or SOLV?
SOLV returned +19.01% over the past 12 months, compared with -57.14% for PODD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PODD or SOLV?
SOLV has the lower trailing P/E at 10.5, versus 25.2 for PODD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Insulet and Solventum in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.